

Ref: COR/2024/11-2(C)
Date: November 14, 2024

**The General Manager,
Pakistan Stock Exchange Limited,
Stock Exchange Building,
Stock Exchange Road,
Karachi.**

MATERIAL INFORMATION

Dear Sir,

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book, we hereby convey the following information:

With reference to the earlier material information disseminated by Ferozsons Laboratories Limited ("the Parent Company") on Pakistan Stock Exchange through its letter ref. FLL/COR/09-2 dated September 09, 2024 wherein it was informed that BF Biosciences Limited ("the Company") has secured approval from Drug Regulatory of Pakistan ("DRAP") for its brownfield expansion project along with commencement of commercial production from pre-filled syringes line.


In continuation of the above, we are pleased to inform that the combi filling and lyophilization lines have been commissioned and commercial production has commenced. Accordingly, the full Line II expansion project stands commissioned from today.

Furthermore, we have already secured approvals for new products from DRAP and intent to launch these products in the coming months, InshAllah.

You are requested to please disseminate the above information to TREC Holders of the Exchange accordingly.

Thank you.

Yours truly,

Abdur Rehman
Company Secretary

CC: Director Enforcement – Securities and Exchange Commission of Pakistan.

Head Office/Biotech Factory:
5 - KM, Sundar Raiwind Road
Raiwind (55150), Pakistan
Tel: (+92 42) 3602 6700
Fax: (+92 42) 3602 6701-02

Registered Office:
197 - A, The Mall, Rawalpindi
(46000), Pakistan
Tel: (+92 51) 4252 155-57
Fax: (+92 51) 4252 153

Lahore Sales Office:
43 - Al Noor Building, Bank
Square, The Mall, Lahore
(54000), Pakistan
Tel: (+92 42) 3735 8194
Fax: (+92 42) 3731 3680

Karachi Sales Office:
House No. 9, Maqbool Cooperative
Housing Society, Shahr-e-Faisal
Karachi (75350), Pakistan
Tel: (+92 21) 3438 6852
Fax: (+92 21) 3438 6754